Purpose: Cancer survivors in a state with no legal access to cannabis may be hesitant to discuss their cannabis use with providers, particularly in light of legal consequences which disproportionately affect certain racial groups. This study examined potential racial disparities in the relationship of cannabis use status with patient-provider discussions of and attitudes toward cannabis in a state where there is no legal cannabis marketplace.
Methods: Survivors of cancer (N = 1003, M = 62.36; 13% Black/African-American; 41% male) completed a cross-sectional survey. Weight-adjusted regressions examined racial differences in the relationship between cannabis use status with (a) comfort and discussion of cannabis with providers, and (b) beliefs about impact of legalization on patients' and providers' comfort discussing cannabis.
Results: No racial differences were observed in rates of cannabis use or discussion, and patients who used cannabis were more comfortable discussing cannabis. Black patients who had used cannabis reported the greatest comfort discussing cannabis with providers, but also the greatest perceived improvement in comfort in the event of legalization.
Conclusions: Results highlight comfort and willingness to discuss cannabis with cancer care providers, particularly among Black patients who already use cannabis, which was not the hypothesized direction of findings. Further work is needed to inform recommendations for provider-led communication about cannabis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-024-09131-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Federal University of Technology Akure, Ondo State, Akure, Nigeria.
Background: The effect of high consumption of psychoactive substances of codeine (CDE), tramadol (TMD), and Cannabis sativa (CNB) as concoction has been associated with altered brain cognitive and neurochemical functions. However, the understanding of the complex mechanism behind the intake of Cannabis sativa co-administration with tramadol and codeine on both cardiac and brain function, neurotransmitters, purinergic, and antioxidant enzymes activities in the brain and heart of rats remains unreported.
Method: The measure of cognition using morris water maze (MWM) and Y-maze tests, hemodynamic parameters namely systolic blood pressure (SBP) and heart rate (HR), acetylcholinesterase (AChE), butyl-cholinesterase (BCHE), adenosine deaminase (ADA), arginase, catalase (CAT), superoxide dismutase (SOD) enzymes' activities, reduced glutathione (GSH) and malondialdehyde (MDA), nitric oxide (NO) levels, in the brain and heart of CNB, TMD, and CDE exposed rats was done.
Three-Month Polysubstance Use Patterns Among People Enrolled in Outpatient Treatment for Methamphetamine Use.
Subst Use Misuse
January 2025
National Centre for Youth Substance Use Research (NCYSUR), School of Psychology, The University of Queensland, Brisbane, Australia.
Background: Polysubstance use is common among people who use methamphetamine. This prospective study examined the three-month polysubstance use profiles among people enrolled in outpatient treatment for methamphetamine use and associated substance use, mental health, and treatment correlates.
Method: The present study used routinely collected client-reported outcome measures data from = 1,507 clients enrolled in outpatient treatment who reported methamphetamine as their primary drug of concern ( = 34.
The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.
J Psychoactive Drugs
January 2025
Department of Psychology, The University of British Columbia, Kelowna, BC, Canada.
The increasing acceptance of cannabis use, and policy changes in several jurisdictions has led researchers and public health experts to call for a standard cannabis dose. Standard dosing units are useful tools for regulation, substance use guidelines, data collection, consistency of research, as a means of communicating low-risk recommendations and dose-related effects, and for self-monitoring. Efforts to standardize cannabis dose have focused on cannabinoid content without considering tolerance or mode.
View Article and Find Full Text PDFObjective: In October 2018, the Government of Canada legalized cannabis for recreational use nationwide. The effects of legalization on cannabis use have been primarily assessed through cross-sectional surveys.
Method: In the present study, a two-wave longitudinal design was used to explore potential demographic, substance use and behavioral addiction, and mental health predictors of change in cannabis use status following legalization.
Legal Recreational Cannabis Sales and Opioid-Related Mortality in the 5 Years Following Cannabis Legalization in Canada: A Granger Causality Analysis.
Cannabis
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton.
Objective: Little is known about the population-level impact of recreational cannabis legalization on trends in opioid-related mortality. Increased access to cannabis due to legalization has been hypothesized to reduce opioid-related deaths because of the potential opioid-sparing effects of cannabis. The objective of this study was to examine the relations between national retail sales of recreational (non-medical) cannabis and opioid overdose deaths in the 5 years following legalization in Canada.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!